CompletedNCT01720095
Niaspan Added to Antipsychotics for Thinking Skills After First-Episode Psychosis
About this title
Read the official source — NCT01720095Medication studyAges 18–35CanadaSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 18 years to 35 years.
- Listed locations
- HalifaxSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateOctober 2009
- Recruitment status
- Completed
- Enrollment listed in the registry
- 22
- Sponsor
- Nova Scotia Health Authority
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Canada
- Age range
- From 18 Years to 35 Years
- Official registry ID
- NCT01720095
- Official title
Show the full official title
A 1 Year Randomized, Controlled, Open-Label Study of the Impact of Flexible Doses of Niacin (NIASPAN) as an Adjunct to Antipsychotic Medication in the Treatment of First Episode Psychosis
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Halifax
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Nova Scotia Health Authority.
Did this study involve medication?
Yes. The study involved medication, including Niaspan.
Who was this study for?
Listed age limits: 18 years to 35 years.
